Tyndall Capital Partners’s Traws Pharma TRAW Stock Holding History

Tyndall Capital Partners’s Portfolio TRAW Stock Details TRAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,644	Closed	-$524K	–	3
2019 Q3	$524K	Sell	1,644 -525	-24%	-$452K	19.34%	2
2019 Q2	$2.32M	Sell	2,169 -8	-0.4%	-$11K	47.11%	2
2019 Q1	$2.69M	Hold	2,177	–	–	53.28%	1
2018 Q4	$1.72M	Hold	2,177	–	–	48.29%	2
2018 Q3	$5.99M	Hold	2,177	–	–	75.56%	1
2018 Q2	$4.95M	Buy	2,177 +1,804	+484%	+$5.24M	71.91%	1
2018 Q1	$1.75M	Buy	373 +196	+111%	+$1.4M	45.59%	2
2017 Q4	$1.5M	Hold	177	–	–	43.06%	2
2017 Q3	$1.71M	Hold	177	–	–	21.79%	2
2017 Q2	$2.15M	Buy	177 +84	+90%	+$1.04M	25.49%	2
2017 Q1	$1.58M	Hold	93	–	–	45.53%	1
2016 Q4	$1.18M	Hold	93	–	–	41.42%	2
2016 Q3	$1.45M	Buy	+93	New	+$1.9M	78.8%	1

Other funds holding TRAW

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

HWA

Hillcrest Wealth Advisors Hazlet, New Jersey $279M AUM 21.72% 1-Year Est. Return

MYDA Advisors Woodmere, New York $672M AUM 71.14% 1-Year Est. Return

Kepos Capital New York $73.4M AUM 4.78% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Tyndall Capital Partners's TRAW Position: Q4 2019 in Review

Tyndall Capital Partners sold out of Traws Pharma (TRAW) in Q4 2019, closing a stake of 1,644 shares — an estimated $524K sold.

Tyndall Capital Partners first reported a position in TRAW in Q3 2016 and held it in 13 quarters. The position peaked at $5.99M in Q3 2018. 18 funds tracked by Wall St. Rank hold TRAW as of Q4 2019.

Tyndall Capital Partners reported no remaining Traws Pharma position as of Q4 2019 after selling out during the quarter.
Tyndall Capital Partners sold 1,644 Traws Pharma shares in Q4 2019, an estimated $524K.
Tyndall Capital Partners first reported a position in Traws Pharma in Q3 2016 and held it in 13 quarters.
Tyndall Capital Partners's Traws Pharma position peaked at $5.99M in Q3 2018.
18 funds tracked by Wall St. Rank held Traws Pharma as of Q4 2019.

Based on Tyndall Capital Partners's 13F filing for Q4 2019, filed 14 Feb 2020.